CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 11 enrolled
Drug / intervention
DPX-E7 vaccine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02865135
NCT02865135Phase 2Completed
CompareCT.gov

A Phase Ib/II Trial To Test The Safety And Efficacy Of Vaccination With HPV16-E711-19 Nanomer For The Treatment Of Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer In HLA-A*02 Positive Patients

Dana-Farber Cancer Institute·interventional·Posted Aug 12, 2016·Updated Jan 11, 2024

In Brief

A Phase 2 clinical trial evaluating DPX-E7 vaccine and Cyclophosphamide for Cancer of Head and Neck and 2 related conditions. Completed, enrolled 11 participants across 1 site.

Detailed Summary

This research study is studying a therapeutic vaccine, named DPX-E7, as a possible treatment for Human Papilloma Virus or HPV related head and neck, cervical or anal cancer (positive for HLA-A\*02).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer of Head and Neck, Cancer of Cervix, Cancer of Anus
CountriesUnited States
CollaboratorsStand Up To Cancer

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedAug 12, 2016
Enrollment StartMar 30, 2017
Primary CompletionOct 4, 2019
Study CompletionFeb 6, 2023
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 9.9 years ago

Interventions

DPX-E7 vaccinedrug

Therapeutic vaccine for the treatment of incurable HPV16-related oropharyngeal, cervical and anal cancer in HLA-A\*02 positive patients.

Cyclophosphamidedrug

Cyclophosphamide is a medication primarily used in the management and treatment of neoplasms, including multiple myeloma, sarcoma, and breast cancer. Cyclophosphamide is a nitrogen mustard that exerts its anti-neoplastic effects through alkylation.